HFB101110 / HiFiBiO, FibroGen - LARVOL DELTA

FibroGen Exercises Exclusive License Option for HiFiBiO’s CCR8 Program (GlobeNewswire) - "FibroGen...and HiFiBiO Therapeutics...announced an extension of their partnership with FibroGen’s exercise of an exclusive license option for HiFiBiO’s anti-CCR8 monoclonal antibody program (HFB1011)....Under the terms of the agreement, HiFiBiO will receive a $35 million upfront payment from FibroGen in addition to potential clinical, regulatory, and commercial milestones. HiFiBiO will also be eligible to receive royalties based upon net sales....The development candidate is expected to enter clinical development in 2023."

Licensing / partnership • New trial • Oncology